It is typically sold under the condition that it is for research purposes only
PubMed Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease Useful when liver-fat claims involve next-generation incretin or pipeline agents
Additional analyses categorized the exposure of GLAs into incretin-based agents (i.e., DPP4is and GLP-1RAs), weight-loss effect agents (i.e., GLP-1RAs and SGLT2is), and newer GLAs (i.e., DPP4is, GLP-1RAs, and SGLT2is) (Supplemental Table 2)
Ozempic (semaglutide): Once-weekly injectable
No, and it is important not to blur these
Evidence remains largely preclinical, but findings indicate possible benefits in reducing inflammation and aiding recovery in digestive tissues, especially in conditions involving ulcers or irritation